Prosecution Insights
Last updated: April 19, 2026

Examiner: GROOMS, TIFFANY NICOLE

Tech Center 1600 • Art Units: 1636 1637 1699

This examiner grants 58% of resolved cases

Performance Statistics

58.5%
Allow Rate
-1.5% vs TC avg
212
Total Applications
+45.8%
Interview Lift
1155
Avg Prosecution Days
Based on 171 resolved cases, 2023–2026

Rejection Statute Breakdown

3.7%
§101 Eligibility
12.5%
§102 Novelty
38.1%
§103 Obviousness
26.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18425219 RNA-Guided Transcriptional Regulation Non-Final OA President and Fellows of Harvard College
16989119 Large Gene Excision and Insertion Non-Final OA President and Fellows of Harvard College
19303600 CAS12 PROTEINS AND USES THEREOF Non-Final OA ZHEJIANG SYNSORBIO TECHNOLOGY CO., LTD.
16625207 Tropism-Modified Recombinant Viral Particles and Uses Thereof for the Targeted Introduction of Genetic Material into Human Cells Final Rejection Regeneron Pharmaceuticals, Inc.
18303533 SITE SPECIFIC GENETIC ENGINEERING UTILIZING TRANS-TEMPLATE RNAS Non-Final OA Massachusetts Institute of Technology
17807405 Compositions, Methods and Systems for the Delivery of Gene Editing Material to Cells Final Rejection Massachusetts Institute of Technology
17631240 COMPOSITIONS AND METHODS FOR TREATING ALPHA THALASSEMIA Non-Final OA THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
18308530 ENHANCEMENT OF SAFETY AND PRECISION FOR CRISPR-Cas INDUCED GENE EDITING BY VARIANTS OF DNA POLYMERASE USING CAS-PLUS VARIANTS Non-Final OA New York University
18392854 COMPOSITIONS COMPRISING A LECITHIN CHOLESTEROL ACYLTRANSFERASE VARIANT AND USES THEREOF Non-Final OA The Trustees of the University of Pennsylvania
18322675 SYSTEMS, METHODS, AND COMPOSITIONS FOR RNA-GUIDED RNA-TARGETING CRISPR EFFECTORS Non-Final OA The University of Tokyo
18247157 MARF/MFN MODULATORS AND USES THEREOF Non-Final OA University of Massachusetts
18498448 COMPOSITIONS AND METHODS FOR ENHANCING GENE EXPRESSION Final Rejection Janssen Pharmaceuticals, Inc.
18295387 CRISPR/CAS9 COMPLEX FOR GENOMIC EDITING Non-Final OA THE UAB RESEARCH FOUNDATION
17911130 GENE INTERFERENCE VECTOR- AND IRON NANOPARTICLE-BASED COMPOSITION FOR KILLING CANCER CELLS, AND USE THEREOF Non-Final OA SOUTHEAST UNIVERSITY
18658840 YEAST STRAINS WITH SELECTED OR ALTERED MITOTYPES AND METHODS OF MAKING AND USING THE SAME Non-Final OA Wisconsin Alumni Research Foundation
17782897 CLINICAL DECISION SUPPORT FOR PERSONALIZED ADAPTIVE PROSTATE CANCER THERAPY Final Rejection H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
18220070 PREVENTION OR TREATMENT OF WASTING SYNDROME Non-Final OA City of Hope
18424838 DUAL-FUNCTIONAL COSMETIC COMPOSITION AND PREPARING METHOD THEREOF Non-Final OA UBIPROTEIN CORP
17821356 CLOSED-END DNA PRODUCTION WITH INVERTED TERMINAL REPEAT SEQUENCES Final Rejection BIOVERATIV THERAPEUTICS INC.
17776993 Method for Detecting Undifferentiated Cells Final Rejection Eiken Kagaku Kabushiki Kaisha
18307000 COMPOSITIONS AND METHODS FOR MODULATING GENE TRANSCRIPTION NETWORKS Final Rejection Nuclear RNA Networks, Inc.
18006075 BIOMARKER SPECIFIC FOR LIVER CANCER, AND USE THEREOF Non-Final OA NEORNAT

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month